These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8668612)

  • 21. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
    Connelly PW; Stachenko S; MacLean DR; Petrasovits A; Little JA
    Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of lipid-lowering treatment in postmenopausal women.
    LaRosa JC
    Drugs Aging; 2002; 19(8):595-604. PubMed ID: 12207553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia].
    Jian J; Hao X; Deng C; Zhou H; Lin J
    Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):517-9. PubMed ID: 11798687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein disorders in women: which women are the best candidates for hormone replacement therapy?
    Plushner SL
    Ann Pharmacother; 1997 Jan; 31(1):98-107. PubMed ID: 8997474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
    Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
    [No Abstract]   [Full Text] [Related]  

  • 26. Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients.
    Gavish D; Leibovitz E; Elly I; Shargorodsky M; Zimlichman R
    Isr Med Assoc J; 2002 Sep; 4(9):694-7. PubMed ID: 12440233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.
    Vedin O; Hagström E; Stewart R; Brown R; Krug-Gourley S; Davies R; Wallentin L; White H; Held C
    Eur J Prev Cardiol; 2013 Aug; 20(4):678-85. PubMed ID: 22496275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Women and ischemic cardiopathy].
    Assmann G; Davignon J; Fernández Cruz A; Gotto AM; Jacotot B; Lewis B; Paoletti R
    Rev Clin Esp; 1989 Oct; 185(6):308-15. PubMed ID: 2695994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing.
    Gerrald KR; Dixon DL; Barnette DJ; Williams VG
    J Clin Lipidol; 2010; 4(2):120-5. PubMed ID: 21122639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A change of attitude in lipidology, achievement of target levels. What comes next?].
    Márk L; Dani G; Kiss Z; Katona A
    Orv Hetil; 2008 Sep; 149(37):1731-6. PubMed ID: 18805756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dietary and pharmacologic therapy for the lipid risk factors.
    JAMA; 1983 Oct; 250(14):1873-9. PubMed ID: 6620484
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of almond dietary supplementation on coronary heart disease lipid risk factors and serum lipid oxidation parameters in men with mild hyperlipidemia.
    Jalali-Khanabadi BA; Mozaffari-Khosravi H; Parsaeyan N
    J Altern Complement Med; 2010 Dec; 16(12):1279-83. PubMed ID: 21114415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lipids in relation to sciatica among Finns.
    Leino-Arjas P; Kauppila L; Kaila-Kangas L; Shiri R; Heistaro S; Heliövaara M
    Atherosclerosis; 2008 Mar; 197(1):43-9. PubMed ID: 17825307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic treatment of hyperlipidemia.
    Last AR; Ference JD; Falleroni J
    Am Fam Physician; 2011 Sep; 84(5):551-8. PubMed ID: 21888306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass.
    Nguyen NT; Varela E; Sabio A; Tran CL; Stamos M; Wilson SE
    J Am Coll Surg; 2006 Jul; 203(1):24-9. PubMed ID: 16798484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary artery disease and diabetes.
    Bohannon NJ
    Postgrad Med; 1999 Feb; 105(2):66-8, 71-2, 77-80. PubMed ID: 10026704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.